Physician profile
Won K Yu
NPI 1720065303
$7,676.14
in general payments reported to CMS, 2019-2025
34 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $719 · 2021: $1,251 · 2022: $1,318 · 2023: $1,235 · 2024: $1,178 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806 · Education: $27.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.00 |
| Education | $27.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,157.68 | 2019-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $1,060.71 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,046.92 | 2019-2024 | Entyvio, Gattex |
| Abbvie INC. | $711.82 | 2020-2025 | Linzess, Viberzi |
| Pfizer INC. | $562.17 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $379.05 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $292.04 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $282.12 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $272.50 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $262.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $244.10 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $150.33 | 2021-2025 | Wegovy |
| Redhill Biopharma INC. | $148.86 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Ferring Pharmaceuticals INC. | $127.80 | 2020-2024 | Rebyota, Clenpiq |
| Daiichi Sankyo INC. | $122.01 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.95 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $80.53 | 2023-2024 | Linzess |
| Celgene Corporation | $62.85 | 2023-2024 | Zeposia |
| Albireo Pharma, INC. | $62.30 | 2024 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $60.84 | 2024-2025 | Voquezna |
| Allergan, INC. | $57.31 | 2019 | |
| Merck Sharp & Dohme LLC | $54.19 | 2019-2020 | |
| Lilly USA, LLC | $48.45 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $44.79 | 2023-2024 | Dupixent |
| Qol Medical, LLC | $41.83 | 2021-2025 | Sucraid |
| Evoke Pharma, INC. | $38.82 | 2022-2023 | Gimoti |
| Vivus LLC | $38.28 | 2023-2024 | Qsymia |
| Ipsen Biopharmaceuticals, INC | $31.72 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $29.57 | 2020 | |
| W. L. Gore & Associates, INC. | $21.25 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.73 | 2022 | |
| Boston Scientific Corporation | $19.39 | 2022 | |
| Grifols USA, LLC | $17.54 | 2020 | |
| Braintree Laboratories, INC. | $15.04 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.